A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis.

Project: Research

StatusActive
Effective start/end date30/05/1929/02/20

Keywords

  • Cystic fibrosis
  • Allergy
  • Immunology
  • Clinical trial
  • Cystic fibrosis
  • Allergy
  • Immunology
  • Clinical trial
  • Cystic fibrosis
  • Allergy
  • Immunology
  • Clinical trial